Verdict: Side-by-side breakdown using the Bull Rankings model. MEDP scored 76.6, DXCM scored 81.5 — DXCM leads.
Compare another set
MEDP
Medpace Holdings, Inc.
Diagnostics & Research · Quality-Growth
76.6
$612.05 · $17.1B
fundamentals as of
Score gap
4.9
DXCM leads
DXCM
DexCom, Inc.
Medical Devices · Quality-Growth
81.5
$84.11 · $31.7B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestDXCM33.4x
Fastest growthMEDP+24.7%
Strongest balance sheetMEDP0.33
Highest qualityDXCM90 / 100
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
MEDP
stronger →← stronger
DXCM
87
Qualityreturns · margins · balance sheet
90
88
Growthrevenue & earnings expansion
89
58
Valuevaluation vs sector peers
67
DXCM is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
MEDP
DXCM
$707mC+
FCF
$1.4bC+
+24.7%A-
Rev
+15.6%B+
0.33B
D/E
0.53B
35.9xC+
P/E
33.4xC+
2.87C
PEG
2.11C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
MEDP
DXCM
26% above
Price vs fair valuelower is cheaper
57% above
~20%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~23%/yr
-37%
1-yr DCF upside
-46%
-21%
5-yr DCF upside
-36%
+10%
10-yr DCF upside
-20%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
MEDP
Why this score
Durable high returns
DXCM
Why this score
Buying back stock
Durable high returns
The companies
MEDPMedpace Holdings, Inc.
Diagnostics & Research · $612.05 · beta 1.18
Why now
Diagnostics & Research · market cap $17.1b. 10% off the 52-week high of $677.90. Revenue growing +25%, comfortably above the S&P median. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $595.92 (implying -3% upside).
Moat
Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 144% of net income, helped by cash released from working capital ($120m) that doesn't repeat every year.
Risk
Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
DXCMDexCom, Inc.
Medical Devices · $84.11 · beta 1.48
Why now
Medical Devices · market cap $31.7b. 9% off the 52-week high of $92.59. Revenue growing +16%, comfortably above the S&P median. 26 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $96.23 (implying +14% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash.
Risk
Beta 1.48 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 33x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where MEDP and DXCM diverge
On the headline score the gap is 4.9 points in favor of DXCM. The widest single difference is Value, where DXCM leads by 8.9 points.
ValueMEDP 58.4 · DXCM 67.3DXCM +8.9
QualityMEDP 87.4 · DXCM 90.4DXCM +3.0
GrowthMEDP 88.3 · DXCM 89.1level
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is DXCM or MEDP the better stock?
DXCM scores higher: DXCM 81.5, MEDP 76.6 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do DXCM and MEDP differ most?
The widest gap is value, where DXCM leads by 9 points on the 0–100 pillar scale. DXCM also leads quality, while growth is effectively level between them.
How are DXCM and MEDP scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.